AbbVie Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Adjusted Earnings Per Share (EPS): $10 for the full year, exceeding guidance by $0.54.

Total Net Revenues: $61.2 billion for the year, surpassing initial guidance by over $2 billion, with an 8.6% sales growth.

Q4 Adjusted EPS: $2.71, $0.08 above guidance.

Q4 Total Net Revenues: $16.6 billion, reflecting a 10% growth.

Adjusted Gross Margin: 83.6% of sales.

R&D Expense: Adjusted R&D expense was 15.4% of sales, totaling nearly $9.7 billion for 2026.

Free Cash Flow: Expected to be $18.5 billion in 2026.

2Strategic Updates and Business Highlights

Pipeline Development: AbbVie advanced 90 clinical programs, with several new product approvals including RINVOQ for GCA and EMERALIS for lung cancer.

Business Development: Invested over $5 billion in new business development, acquiring innovative technologies and products, including a CAR T platform and a next-generation psychedelic for depression.

Oncology Portfolio: Strengthened with new acquisitions, including a PD-1 VEGF bispecific antibody.

Neuroscience Growth: Notable growth in Vraylar and the launch of Violet for Parkinson's disease, expected to achieve blockbuster status in 2026.

3Forward Guidance and Outlook

2026 Revenue Growth: Expected total sales growth of 9.5%, with total net revenues projected around $67 billion.

Key Product Forecasts:

Immunology sales expected at $34.5 billion.

Neuroscience sales projected at $12.5 billion.

Oncology sales anticipated at $6.5 billion.

Aesthetics sales expected at $5 billion.

Adjusted EPS Guidance for 2026: Between $14.37 and $14.57.

4Bad News, Challenges, or Points of Concern

HUMIRA Erosion: Experienced nearly $16 billion in revenue erosion due to biosimilar competition, with expectations for further declines in 2026.

Pricing Pressures: Anticipated low single-digit pricing headwinds for SKYRIZI and RINVOQ in 2026.

Competitive Pressures: Increasing competition in immunology, particularly with new entrants in the IBD market, could impact SKYRIZI's market share.

Oncology Challenges: IMBRUVICA faced a 20.8% decline in sales due to competitive dynamics and IRA pricing impacts.

5Notable Q&A Insights

Immunology Franchise: SKYRIZI's performance remains strong despite competition, with high capture rates in the IBD market. AbbVie is confident in its growth potential, bolstered by upcoming data readouts.

Business Development Strategy: AbbVie is open to both early and late-stage asset acquisitions to enhance its pipeline, focusing on immunology, neuroscience, and oncology.

Migraine Market Expansion: AbbVie is expanding its presence in primary care for migraine treatments, with strong performance from UBRELVY and QLIPTA.

Regulatory and Competitive Landscape: Concerns were raised about potential competition from IL-15 therapies in vitiligo, but AbbVie remains optimistic about RINVOQ’s positioning in the market. This summary encapsulates AbbVie's strong performance in 2025, strategic advancements, and the challenges ahead as they navigate a competitive landscape while maintaining growth momentum.